{"id":"NCT04842747","sponsor":"Veru Inc.","briefTitle":"VERU-111 in the Treatment of SARS-Cov-2 Infection by Assessing Its Effect on the Proportion of Patients Who Die on Study","officialTitle":"Phase 3, Randomized, Placebo-Controlled, Efficacy and Safety Study of VERU-111 for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Patients at High Risk for Acute Respiratory Distress Syndrome (ARDS).","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-05-18","primaryCompletion":"2022-07-06","completion":"2022-07-06","firstPosted":"2021-04-13","resultsPosted":"2023-04-18","lastUpdate":"2023-04-18"},"enrollment":204,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["SARS-CoV Infection"],"interventions":[{"type":"DRUG","name":"VERU-111","otherNames":["Sabizabulin"]}],"arms":[{"label":"9mg of VERU-111 Oral daily","type":"EXPERIMENTAL"},{"label":"Placebo Capsule once daily","type":"NO_INTERVENTION"}],"summary":"To demonstrate the efficacy of VERU-111 in the treatment of SARS-Cov-2 Infection by assessing its effect on the proportion of patients who die on study (prior to Day 60).","primaryOutcome":{"measure":"Efficacy of Sabizabulin in the Treatment of SARS-CoV-2 Infection by Assessing Its Effect on the Proportion of Patients Who Died on Study.","timeFrame":"Day 60","effectByArm":[{"arm":"9mg of VERU-111 Oral Daily","deltaMin":25,"sd":null},{"arm":"Placebo Capsule Once Daily","deltaMin":27,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":14},"locations":{"siteCount":58,"countries":["United States","Argentina","Brazil","Bulgaria","Colombia","Mexico"]},"refs":{"pmids":["38319812"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":38,"n":130},"commonTop":["Respiratory failure","Acute kidney injury","Pneumonia","Constipation","Hypotension"]}}